| Dr Andrew Paul Walker, MD | |
|
3200 Maccorkle Ave Se, Camc Memorial Hospital, Surgicare Center, Charleston, WV 25304-1227 | |
| (304) 388-8238 | |
| Not Available |
| Full Name | Dr Andrew Paul Walker |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 9 Years |
| Location | 3200 Maccorkle Ave Se, Charleston, West Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306227384 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 29867 (West Virginia) | Primary |
| 390200000X | Student In An Organized Health Care Education/training Program | (* (Not Available)) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Charleston Area Medical Center | Charleston, WV | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Charleston Area Medical Center Inc | 3375441637 | 675 |
News Archive
In this post in the Center for Global Development's "Global Health Policy" blog, Amanda Glassman, director of global health policy and a research fellow at the center, writes that the "main outcome" of the U.N. High-level Meeting on Non-Communicable Diseases (NCDs) is an assignment for the WHO "to lead the global response to NCDs, develop a monitoring and evaluation framework, provide technical assistance and track progress towards global targets."
According to the American Diabetes Association, diabetes affects as many as 21 million Americans increasing their risk of heart attacks, kidney disease and blindness.
Debiopharm Group, a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs as well as companion diagnostics, today announced the launch of a Phase 1 dose-escalation study of Debio 1450 (previously known as AFN-1720), a highly potent anti-infective agent that is selectively active against a large number of Staphylococcus species, including all known resistant strains such as methicillin-resistant S. aureus (MRSA) and vancomycin-intermediate S. aureus (VISA).
Cardium Therapeutics today announced that it was awarded a cash grant of approximately $245,000 under the U.S. Government's Qualifying Therapeutic Discovery Project program to further its Generx clinical development program.
In an effort to mitigate the spread of COVID-19 and to optimize allocation of healthcare resources, researchers are improving ways to treat patients with acute large vessel occlusion strokes in a safe manner that also better protects health care workers.
› Verified 5 days ago
| Entity Name | Charleston Area Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124248752 PECOS PAC ID: 3375441637 Enrollment ID: O20031223000426 |
News Archive
In this post in the Center for Global Development's "Global Health Policy" blog, Amanda Glassman, director of global health policy and a research fellow at the center, writes that the "main outcome" of the U.N. High-level Meeting on Non-Communicable Diseases (NCDs) is an assignment for the WHO "to lead the global response to NCDs, develop a monitoring and evaluation framework, provide technical assistance and track progress towards global targets."
According to the American Diabetes Association, diabetes affects as many as 21 million Americans increasing their risk of heart attacks, kidney disease and blindness.
Debiopharm Group, a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs as well as companion diagnostics, today announced the launch of a Phase 1 dose-escalation study of Debio 1450 (previously known as AFN-1720), a highly potent anti-infective agent that is selectively active against a large number of Staphylococcus species, including all known resistant strains such as methicillin-resistant S. aureus (MRSA) and vancomycin-intermediate S. aureus (VISA).
Cardium Therapeutics today announced that it was awarded a cash grant of approximately $245,000 under the U.S. Government's Qualifying Therapeutic Discovery Project program to further its Generx clinical development program.
In an effort to mitigate the spread of COVID-19 and to optimize allocation of healthcare resources, researchers are improving ways to treat patients with acute large vessel occlusion strokes in a safe manner that also better protects health care workers.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Andrew Paul Walker, MD 3200 Maccorkle Ave Se, Camc Memorial Hospital, Surgicare Center, Charleston, WV 25304-1227 Ph: (304) 388-8238 | Dr Andrew Paul Walker, MD 3200 Maccorkle Ave Se, Camc Memorial Hospital, Surgicare Center, Charleston, WV 25304-1227 Ph: (304) 388-8238 |
News Archive
In this post in the Center for Global Development's "Global Health Policy" blog, Amanda Glassman, director of global health policy and a research fellow at the center, writes that the "main outcome" of the U.N. High-level Meeting on Non-Communicable Diseases (NCDs) is an assignment for the WHO "to lead the global response to NCDs, develop a monitoring and evaluation framework, provide technical assistance and track progress towards global targets."
According to the American Diabetes Association, diabetes affects as many as 21 million Americans increasing their risk of heart attacks, kidney disease and blindness.
Debiopharm Group, a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs as well as companion diagnostics, today announced the launch of a Phase 1 dose-escalation study of Debio 1450 (previously known as AFN-1720), a highly potent anti-infective agent that is selectively active against a large number of Staphylococcus species, including all known resistant strains such as methicillin-resistant S. aureus (MRSA) and vancomycin-intermediate S. aureus (VISA).
Cardium Therapeutics today announced that it was awarded a cash grant of approximately $245,000 under the U.S. Government's Qualifying Therapeutic Discovery Project program to further its Generx clinical development program.
In an effort to mitigate the spread of COVID-19 and to optimize allocation of healthcare resources, researchers are improving ways to treat patients with acute large vessel occlusion strokes in a safe manner that also better protects health care workers.
› Verified 5 days ago
Ghulam Abbas, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 3100 Maccorkle Ave Se Ste 101, Charleston, WV 25304 Phone: 304-388-5395 Fax: 304-388-5398 | |
Dr. Jacob Minor, DO Surgery Medicare: Medicare Enrolled Practice Location: 3100 Maccorkle Ave Se Ste 700, Charleston, WV 25304 Phone: 304-351-1600 Fax: 304-351-1604 | |
Edward Henry Tiley Iii, M.D. Surgery Medicare: Medicare Enrolled Practice Location: 9 Courtney Dr, Charleston, WV 25304 Phone: 304-925-3115 Fax: 304-925-2088 | |
Dr. Luke Weldon Martin, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 331 Laidley St Ste 503, Charleston, WV 25301 Phone: 304-205-7912 Fax: 304-205-4694 | |
Dr. Shadi J Abu-halimah, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 415 Morris St, Suite 105, Charleston, WV 25301 Phone: 304-388-6412 Fax: 304-388-6416 | |
Dr. Michael Elmore, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 3100 Maccorkle Ave Se, Ste 700, Charleston, WV 25304 Phone: 304-556-3810 Fax: 304-347-1397 | |
Dr. Eric P Mantz, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 600 Morris St, Suite 103, Charleston, WV 25301 Phone: 304-388-7040 Fax: 304-388-7041 |